Point-of-care molecular diagnostics instrumentation
Biocartis is a commercial stage company which develops novel molecular diagnostics. The proprietary Idylla™ platform is a fully automated, real-time system which provides accurate, highly-reliable RNA and protein expression information from any biological sample, thus improving diagnosis and facilitating personalised therapy at the point of care.
CEO Rudi Pauwels
Advent invested in the Series A in 2009. Biocartis listed on Euronext Brussels in 2015 (EBR:BCART).
Biocartis raises eur 100 million in successful initial public offering
Press Release. Mechelen, Belgium, 24 April 2015 – Biocartis Group NV (the “Company” or “Biocartis”), an innovative molecular diagnostics company, today announces the results of its initial public offering,…Read More
Biocartis raises eur 64.5 million (approx. USD 85 million)
Press Release. Investment supports commercial roll-out of Idylla™, Biocartis’ flagship molecular diagnostics system, and the development of the system’s menu of diagnostics tests. Mechelen (Belgium), September 4, 2014…Read More
Biocartis completes €34,5million ($44,5 million) Series D Fund Raising
Press Release. Capital to be used to commercialize recently launched DMAT platform, validate APOLLO platform and build proprietary oncology content on both platforms. Strong support from internal shareholders and…Read More
Biocartis announces commercial launch of a new biomarker analysis platform
Press Release. Lausanne, Switzerland – 5 December 2012 Biocartis launches its revolutionary detection platform, Dynamic Multi-Analyte Technology (“DMAT”): New proteomic and nucleic acid platform provides ultra-high quality data analysis…Read More